Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDSNASDAQ:CALANASDAQ:EFTRNASDAQ:EVLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDSAridis Pharmaceuticals$0.00-66.7%$0.00$0.00▼$0.08$5K12.427,856 shs359 shsCALACalithera Biosciences$0.00+35.7%$0.00$0.00▼$0.12$19K-2.3817,319 shs100 shsEFTReFFECTOR Therapeutics$0.00$0.00▼$1.74N/A0.422,826 shs2 shsEVLOEvelo Biosciences$0.00+400.0%$0.00$0.00▼$0.06$38K0.7714,228 shs98,767 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDSAridis Pharmaceuticals0.00%-50.00%0.00%0.00%-99.84%CALACalithera Biosciences0.00%+366.67%-44.00%+366.67%-72.00%EFTReFFECTOR Therapeutics0.00%-95.00%-50.00%-50.00%-99.99%EVLOEvelo Biosciences0.00%0.00%+33.33%-84.00%-33.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDSAridis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AEFTReFFECTOR TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDSAridis Pharmaceuticals 0.00N/AN/AN/ACALACalithera Biosciences 0.00N/AN/AN/AEFTReFFECTOR Therapeutics 0.00N/AN/AN/AEVLOEvelo Biosciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDSAridis Pharmaceuticals$3.09M0.00N/AN/AN/A∞CALACalithera BiosciencesN/AN/AN/AN/AN/AN/AEFTReFFECTOR Therapeutics$3.55M0.00N/AN/A($1.94) per share0.00EVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDSAridis Pharmaceuticals-$30.37MN/A0.00∞N/AN/AN/AN/AN/ACALACalithera Biosciences-$39.65MN/A0.00∞N/AN/AN/AN/AN/AEFTReFFECTOR Therapeutics-$35.81M-$13.08N/AN/AN/AN/AN/AN/A7/28/2025 (Estimated)EVLOEvelo Biosciences-$114.53MN/A0.00∞N/AN/AN/AN/A7/7/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDSAridis PharmaceuticalsN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AEFTReFFECTOR TherapeuticsN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDSAridis Pharmaceuticals9.65%CALACalithera BiosciencesN/AEFTReFFECTOR Therapeutics57.67%EVLOEvelo Biosciences0.31%Insider OwnershipCompanyInsider OwnershipARDSAridis Pharmaceuticals5.50%CALACalithera Biosciences6.60%EFTReFFECTOR Therapeutics4.70%EVLOEvelo Biosciences1.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDSAridis Pharmaceuticals3053.32 million50.39 millionNot OptionableCALACalithera Biosciences604.87 million4.55 millionNot OptionableEFTReFFECTOR Therapeutics104.70 million4.48 millionNo DataEVLOEvelo Biosciences12018.98 million18.79 millionNo DataCALA, ARDS, EFTR, and EVLO HeadlinesRecent News About These CompaniesEvelo Biosciences Target of Unusually High Options Trading (NASDAQ:EVLO)May 30 at 3:35 AM | americanbankingnews.comEvelo's Compass E-Trike Has Comfort, Range, and Even Power; Priced Decently Well, TooApril 17, 2025 | autoevolution.comEvelo Biosciences (OTC:EVLO) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comEvelo Biosciences (OTC:EVLO) Stock, Insider Trading ActivityOctober 4, 2024 | benzinga.comEVLO Expands Portfolio with Launch of EVLO SYNERGY - A High-Density 5 MWh Battery Storage SolutionAugust 30, 2024 | ca.finance.yahoo.comEvelo Biosciences, Inc. (EVLO)August 24, 2024 | nz.finance.yahoo.comEvelo Biosciences Stock (OTC:EVLO), Short Interest ReportFebruary 22, 2024 | benzinga.comEvelo Biosciences: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of ListingDecember 6, 2023 | cbonds.comEvelo Biosciences, a microbiome company launched by Flagship, shuts downNovember 24, 2023 | msn.comEvelo Bio Shutdown Follows a Series of Microbiome Therapy Trial FailuresNovember 23, 2023 | medcitynews.comFlagship-backed startup Evelo, behind failed eczema drug, to dissolveNovember 22, 2023 | bizjournals.comEvelo’s voyage ends, as Flagship-founded biotech finds dissolution is only viable optionNovember 22, 2023 | fiercebiotech.comFMR LLC Reduces Stake in Evelo Biosciences IncNovember 14, 2023 | finance.yahoo.comEvelo Biosciences Inc EVLONovember 10, 2023 | morningstar.comPresident & CEO GILL SIMBA sale 1,996 shares of Evelo Biosciences Inc [EVLO]November 3, 2023 | knoxdaily.comQ3 2023 Horizon Technology Finance Corp Earnings CallNovember 2, 2023 | finance.yahoo.comHorizon Technology Finance Corporation (NASDAQ:HRZN) Q3 2023 Earnings Call TranscriptNovember 2, 2023 | finance.yahoo.comEvelo Biosciences (EVLO) Price Target Increased by 53.85% to 10.20November 1, 2023 | msn.comEVLO shares expected to outperform in the next 12 monthsOctober 26, 2023 | knoxdaily.comTD Cowen Downgrades Evelo Biosciences (EVLO)October 19, 2023 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsPfizer's 7.5% Dividend: Income Haven or House of Cards?By Jeffrey Neal Johnson | May 23, 2025View Pfizer's 7.5% Dividend: Income Haven or House of Cards?Archer Rebuts Short Seller, Points to Strong Q1 & Global MomentumBy Jeffrey Neal Johnson | May 22, 2025View Archer Rebuts Short Seller, Points to Strong Q1 & Global MomentumJoby's Q1: Key Milestones Achieved as Path to Market CrystalizesBy Jeffrey Neal Johnson | May 8, 2025View Joby's Q1: Key Milestones Achieved as Path to Market CrystalizesCALA, ARDS, EFTR, and EVLO Company DescriptionsAridis Pharmaceuticals NASDAQ:ARDS$0.0001 0.00 (-66.67%) As of 10:35 AM EasternAridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.Calithera Biosciences NASDAQ:CALA$0.0038 +0.00 (+35.71%) As of 10:10 AM EasternCalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.eFFECTOR Therapeutics NASDAQ:EFTReFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.Evelo Biosciences NASDAQ:EVLO$0.0020 +0.00 (+400.00%) As of 09:48 AM EasternEvelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Ackman Takes a Swing at Amazon — Should You? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
